cannabidiol + semaglutide

Cannabidiol + semaglutide is a **combination of two active substances**: cannabidiol (CBD), a non-intoxicating cannabinoid derived from cannabis, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. - **Cannabidiol** is believed to act through multiple targets in the endocannabinoid system, primarily cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R), with potential anti-inflammatory, anxiolytic, and neuroprotective effects. - **Semaglutide** is a GLP-1 receptor agonist that mimics endogenous GLP-1, stimulating the GLP-1 receptor to enhance insulin secretion, suppress glucagon, slow gastric emptying, suppress appetite, and facilitate weight loss. - This combination is under early investigation for metabolic disorders, such as obesity and hypertriglyceridemia, and there is preclinical and early clinical interest in substance use disorders such as cannabis use disorder. - No approved pharmaceutical formulations combining these two agents currently exist; however, a Phase 1 trial is evaluating "DehydraTECH-CBD in combination with DehydraTECH-semaglutide" in overweight or obese participants with and without type 2 diabetes[3].

Other names

DehydraTECH-CBD + DehydraTECH-semaglutideDehydraTECH-CBD + semaglutide